Feyer Petra, Seegenschmiedt M Heinrich, Steingraeber Maria
Clinic of Radiooncology and Nuclear Medicine, Vivantes Clinics Neukoelln, 12351 Berlin, Germany.
Support Care Cancer. 2005 Sep;13(9):671-8. doi: 10.1007/s00520-004-0766-3. Epub 2005 Jul 26.
Radiotherapy-induced nausea and vomiting (RINV) can be one of the most distressing symptoms of radiotherapy treatment, which if incompletely controlled may last for several weeks with fractionated radiotherapy and prevent completion of the planned treatment course. Current treatment guidelines recommend the use of 5-HT(3) receptor antagonists with or without corticosteroids for highly and moderately emetogenic radiotherapy, though only granisetron and ondansetron are currently indicated for RINV in most countries. Granisetron is a potent and highly selective 5-HT(3) receptor antagonist, with demonstrated efficacy in RINV in both placebo-controlled and comparative studies. In this paper the clinical experience with granisetron in RINV is reviewed, and its efficacy and safety compared with other antiemetic therapies.
放射治疗引起的恶心和呕吐（RINV）可能是放射治疗中最令人痛苦的症状之一，如果控制不完全，在分次放射治疗中可能持续数周，并妨碍完成计划的治疗疗程。目前的治疗指南推荐在高度和中度致吐性放射治疗中使用5-HT(3)受体拮抗剂，可联合或不联合使用糖皮质激素，尽管目前在大多数国家只有格拉司琼和昂丹司琼被批准用于RINV。格拉司琼是一种强效且高度选择性的5-HT(3)受体拮抗剂，在安慰剂对照研究和比较研究中均显示出对RINV有效。本文回顾了格拉司琼治疗RINV的临床经验，并将其疗效和安全性与其他止吐疗法进行比较。
